{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:32:11Z","timestamp":1790163131931,"version":"4.1.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,2]],"date-time":"2020-01-02T00:00:00Z","timestamp":1577923200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,1,2]],"date-time":"2020-01-02T00:00:00Z","timestamp":1577923200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Res Notes"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Objectives<\/jats:title>\n<jats:p>Anti-tuberculosis drug-induced hepatotoxicity is a common serious adverse drug reaction. This study intended to determine the prevalence and associated factors of drug-induced hepatotoxicity among tuberculosis and human immunodeficiency virus co-infected patients in Dessie referral hospital northeast Ethiopia.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>In this cross-sectional study 84 patients were enrolled retrospectively. Data from September 1\/2015 to August 30\/2018 were extracted from March 1\/2019 to April 1\/2019. Association between dependent and independent variables was determined using the odds ratio and a <jats:italic>P<\/jats:italic> value of\u2009&lt;\u20090.05 was considered as statistical significance. Out of 84 patients, 17 patients developed drug-induced hepatotoxicity which makes the prevalence of drug-induced hepatotoxicity 20.2%. The result revealed that the presence of disseminated or extrapulmonary tuberculosis [(AOR: 7.728, 95% CI (1.516\u201339.404)] and\/or body mass index less than 18.5\u00a0kg\/m<jats:sup>2<\/jats:sup> [(AOR\u2009=\u20095.593, 95% CI (1.180\u201326.519)] were a risk factor for drug-induced hepatotoxicity. Tuberculosis and human immunodeficiency virus co-infected patients with extra- pulmonary tuberculosis and\/or body mass index less than 18.5\u00a0kg\/m2 should be closely followed and supervised for the development of hepatotoxicity.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s13104-019-4872-1","type":"journal-article","created":{"date-parts":[[2020,1,2]],"date-time":"2020-01-02T14:02:59Z","timestamp":1577973779000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Drug-induced hepatotoxicity among TB\/HIV co-infected patients in a referral hospital, Ethiopia"],"prefix":"10.1186","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2900-207X","authenticated-orcid":false,"given":"Abebe","family":"Zeleke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bethelihem","family":"Misiker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teshager Aklilu","family":"Yesuf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,2]]},"reference":[{"key":"4872_CR1","unstructured":"Organization WH. Global Tuberculosis Report 2014. World Health Organization; 2014."},{"key":"4872_CR2","unstructured":"Organization WH. Global tuberculosis report 2013: World Health Organization; 2013."},{"issue":"5","key":"4872_CR3","doi-asserted-by":"publisher","first-page":"e64622","DOI":"10.1371\/journal.pone.0064622","volume":"8","author":"AH Ali","year":"2013","unstructured":"Ali AH, Belachew T, Yami A, Ayen WY. Anti-tuberculosis drug induced hepatotoxicity among TB\/HIV co-infected patients at Jimma University Hospital, Ethiopia: nested case-control study. PLoS ONE. 2013;8(5):e64622.","journal-title":"PLoS ONE"},{"issue":"3","key":"4872_CR4","doi-asserted-by":"publisher","first-page":"e1809","DOI":"10.1371\/journal.pone.0001809","volume":"3","author":"G Yimer","year":"2008","unstructured":"Yimer G, Aderaye G, Amogne W, Makonnen E, Aklillu E, Lindquist L, et al. Anti-tuberculosis therapy-induced hepatotoxicity among Ethiopian HIV-positive and negative patients. PLoS ONE. 2008;3(3):e1809.","journal-title":"PLoS ONE"},{"key":"4872_CR5","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1590\/S0102-311X2012000400009","volume":"28","author":"MF Lima","year":"2012","unstructured":"Lima MF, Melo HR. Hepatotoxicity induced by antituberculosis drugs among patients coinfected with HIV and tuberculosis. Cadernos de saude publica. 2012;28:698\u2013708.","journal-title":"Cadernos de saude publica."},{"key":"4872_CR6","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.30875\/77ef1805-en","volume-title":"WHO report 2010: global tuberculosis control","author":"WH Organization","year":"2010","unstructured":"Organization WH. WHO report 2010: global tuberculosis control. Geneva: World Health Organization; 2010. p. 2011."},{"key":"4872_CR7","unstructured":"Assob J, Nde P, Nsagha D, Njunda A, Ngum N, Ngowe M. Incidence and risk factors of anti-tuberculosis drugs induced hepatotoxicity in HIV\/AIDS patients attending the Limbe and Buea Regional Hospitals. J AIDS Clin Res. 2014;5(3)."},{"key":"4872_CR8","unstructured":"Benson CA, Brooks JT, Holmes KK, Kaplan JE, Masur H, Pau A. Guidelines for prevention and treatment opportunistic infections in HIV-infected adults and adolescents; recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association\/Infectious Diseases Society of America. 2009."},{"issue":"7","key":"4872_CR9","doi-asserted-by":"publisher","first-page":"e21836","DOI":"10.1371\/journal.pone.0021836","volume":"6","author":"P Shang","year":"2011","unstructured":"Shang P, Xia Y, Liu F, Wang X, Yuan Y, Hu D, et al. Incidence, clinical features and impact on anti-tuberculosis treatment of anti-tuberculosis drug induced liver injury (ATLI) in China. PLoS ONE. 2011;6(7):e21836.","journal-title":"PLoS ONE"},{"issue":"2","key":"4872_CR10","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.ccm.2005.02.002","volume":"26","author":"WJ Burman","year":"2005","unstructured":"Burman WJ. Issues in the management of HIV-related tuberculosis. Clin Chest Med. 2005;26(2):283\u201394.","journal-title":"Clin Chest Med"},{"issue":"5","key":"4872_CR11","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1056\/NEJMra021844","volume":"349","author":"WM Lee","year":"2003","unstructured":"Lee WM. Drug-induced hepatotoxicity. N Engl J Med. 2003;349(5):474\u201385.","journal-title":"N Engl J Med"},{"issue":"7","key":"4872_CR12","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1164\/ajrccm.164.7.2109052","volume":"164","author":"WJ Burman","year":"2001","unstructured":"Burman WJ, Reves RR. Hepatotoxicity from rifampin plus pyrazinamide: lessons for policymakers and messages for care providers. Am J Respir Crit Care Med. 2001;164(7):1112\u20133.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"4872_CR13","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.ijmyco.2016.05.003","volume":"5","author":"W Ngouleun","year":"2016","unstructured":"Ngouleun W, Nya PCB, Pieme AC, Telefo PB. Risk assessment of hepatotoxicity among tuberculosis and human immunodeficiency virus\/AIDS-coinfected patients under tuberculosis treatment. Int J Mycobacteriol. 2016;5(4):482\u20138.","journal-title":"Int J Mycobacteriol"}],"container-title":["BMC Research Notes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-019-4872-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13104-019-4872-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-019-4872-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:27:22Z","timestamp":1609460842000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcresnotes.biomedcentral.com\/articles\/10.1186\/s13104-019-4872-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,2]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["4872"],"URL":"https:\/\/doi.org\/10.1186\/s13104-019-4872-1","relation":{},"ISSN":["1756-0500"],"issn-type":[{"value":"1756-0500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,2]]},"assertion":[{"value":"11 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Before study initiation, ethical clearance of Wollo University Ethical Board was obtained. An official letter from Wollo University explaining the purpose of the study was submitted to the hospital administration and support of the administration is obtained before pursuing the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publish"}},{"value":"The authors declare that they have no competing of interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2"}}